SCHEMBL17239474

SCHEMBL17239474

COC(=O)c1cc(-c2ccccn2)c(OC)cc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 2/20 0.56
GABRG2 P18507 1/20 0.48
GABRB3 P28472 1/20 0.48
GABRA3 P34903 1/20 0.48
GRM4 Q14833 3/20 0.46
HDAC6 Q9UBN7 1/20 0.46
AXL P30530 1/20 0.46
SLC6A4 P31645 1/20 0.45
SLC6A3 Q01959 1/20 0.45
S1PR1 P21453 1/20 0.44
GRM5 P41594 1/20 0.44
NPC1 O15118 2/20 0.44
MEN1 O00255 1/20 0.44
TP53 P04637 1/20 0.44
GAA P10253 1/20 0.44
RAB9A P51151 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KDM4E B2RXH2 1/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17239475 0.88 NTRK1 (0.57) NTRK1GRM4HDAC6S1PR1NPC1
SCHEMBL17239448 0.88 NTRK1 (0.51) NTRK1GABRG2GABRB3GABRA3AXL
SCHEMBL30304318 0.88 NTRK1 (0.51) NTRK1GABRG2GABRB3GABRA3AXL
SCHEMBL17239501 0.86 NTRK1 (0.53) NTRK1GABRG2GABRB3GABRA3AXL
SCHEMBL17239550 0.85 NTRK1 (0.53) NTRK1
SCHEMBL8704331 0.79 SLC6A3 (0.50) GABRG2GABRB3GABRA3AXLSLC6A4
SCHEMBL5234641 0.79 SLC6A3 (0.55) GABRG2GABRB3GABRA3AXLSLC6A4
SCHEMBL29694130 0.79 SLC6A3 (0.55) GABRG2GABRB3GABRA3AXLSLC6A4
SCHEMBL13117486 0.77 HTT (0.49) HDAC6GRM5NPC1TP53GAA
SCHEMBL1788339 0.77 P2RX7 (0.58) NTRK1GABRG2GABRB3GABRA3GRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3140298-A1 TROPOMYOSIN-RELATED KINASE INHIBITORS Pfizer Inc. (US) 2017-03-15 EP disclosed
US-9328096-B2 Tropomyosin-related kinase inhibitors PFIZER INC. (US) 2016-05-03 US disclosed
US-9328096-B2 Tropomyosin-related kinase inhibitors PFIZER INC. (US) 2016-05-03 US disclosed
US-20150322043-A1 TROPOMYOSIN-RELATED KINASE INHIBITORS PFIZER (US) 2015-11-12 US disclosed
US-20150322043-A1 TROPOMYOSIN-RELATED KINASE INHIBITORS PFIZER (US) 2015-11-12 US disclosed
WO-2015170218-A1 TROPOMYOSIN-RELATED KINASE INHIBITORS PFIZER INC. (US) 2015-11-12 WO disclosed
WO-2015170218-A1 TROPOMYOSIN-RELATED KINASE INHIBITORS PFIZER INC. (US) 2015-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322043-A1 TROPOMYOSIN-RELATED KINASE INHIBITORS TPM3, MUSK, TPM4 NTRK1 8/4885GABRG2 1730/4885GABRB3 1050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.